175 related articles for article (PubMed ID: 17000680)
21. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Schmittel A; Schuster R; Bechrakis NE; Siehl JM; Foerster MH; Thiel E; Keilholz U
Melanoma Res; 2005 Oct; 15(5):447-51. PubMed ID: 16179873
[TBL] [Abstract][Full Text] [Related]
22. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
23. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
25. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
[TBL] [Abstract][Full Text] [Related]
26. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
27. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
29. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Peng RQ; Ding Y; Zhang X; Liao Y; Zheng LM; Zhang XS
Cancer Biol Ther; 2012 Dec; 13(14):1443-8. PubMed ID: 22954698
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Ribas A; Puzanov I; Dummer R; Schadendorf D; Hamid O; Robert C; Hodi FS; Schachter J; Pavlick AC; Lewis KD; Cranmer LD; Blank CU; O'Day SJ; Ascierto PA; Salama AK; Margolin KA; Loquai C; Eigentler TK; Gangadhar TC; Carlino MS; Agarwala SS; Moschos SJ; Sosman JA; Goldinger SM; Shapira-Frommer R; Gonzalez R; Kirkwood JM; Wolchok JD; Eggermont A; Li XN; Zhou W; Zernhelt AM; Lis J; Ebbinghaus S; Kang SP; Daud A
Lancet Oncol; 2015 Aug; 16(8):908-18. PubMed ID: 26115796
[TBL] [Abstract][Full Text] [Related]
32. Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer.
Kim JH; Lee KW; Kim YH; Lee KH; Oh DY; Kim J; Yang SH; Im SA; Choi SH; Bang YJ
J Korean Med Sci; 2010 May; 25(5):684-90. PubMed ID: 20436702
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma.
Neale MH; Myatt NE; Khoury GG; Weaver P; Lamont A; Hungerford JL; Kurbacher CM; Hall P; Corrie PG; Cree IA
Melanoma Res; 2001 Dec; 11(6):601-9. PubMed ID: 11725206
[TBL] [Abstract][Full Text] [Related]
34. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract][Full Text] [Related]
35. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
[TBL] [Abstract][Full Text] [Related]
36. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
37. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
39. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Glaysher S; Gabriel FG; Johnson P; Polak M; Knight LA; Parker K; Poole M; Narayanan A; Cree IA;
Br J Cancer; 2010 Aug; 103(5):656-62. PubMed ID: 20700122
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
